Daniel Bensen
Fondateur chez TYRA BIOSCIENCES, INC.
Fortune : 7 M $ au 30/04/2024
Profil
Daniel Bensen is the founder and the Chief Operating Officer of Tyra Biosciences, Inc., a company founded in 2018.
He previously worked as a Principal Scientist at Trius Therapeutics, Inc. from 2007 to 2014, and as the Head-Immunology & Protein Chemistry at Cidara Therapeutics, Inc. from 2014 to 2018.
Mr. Bensen obtained his undergraduate degree from Point Loma Nazarene University and an MBA from USC Marshall School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TYRA BIOSCIENCE, INC
0,82% | 11/03/2024 | 431 683 ( 0,82% ) | 7 M $ | 30/04/2024 |
Postes actifs de Daniel Bensen
| Sociétés | Poste | Début |
|---|---|---|
| TYRA BIOSCIENCES, INC. | Fondateur | 02/08/2018 |
Anciens postes connus de Daniel Bensen
| Sociétés | Poste | Fin |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2018 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/02/2014 |
Formation de Daniel Bensen
| Point Loma Nazarene University | Undergraduate Degree |
| USC Marshall School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| TYRA BIOSCIENCES, INC. | Health Technology |
| CIDARA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
